Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000905148-25-000984
Filing Date
2025-03-20
Accepted
2025-03-20 18:08:37
Documents
1
Period of Report
2025-03-18

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 3887
  Complete submission text file 0000905148-25-000984.txt   5477
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Issuer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)

Mailing Address C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD SUITE 455 ROCKVILLE MD 20850
Business Address
Swirsky Douglas J (Reporting) CIK: 0001375884 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40674 | Film No.: 25758010